Aldeyra Therapeutics Reports FDA Type A Meeting Minutes; Plans Type D

What Happened

• Aldeyra Therapeutics announced it received minutes on July 14, 2026 from a Type A meeting with the U.S. Food and Drug Administration held June 10, 2026 concerning a potential resubmission of its New Drug Application (NDA) for reproxalap to treat dry eye disease.
• On July 15, 2026 Aldeyra requested clarification of those Minutes from the FDA and said it intends to request a Type D meeting to discuss potential NDA resubmission; the Type D meeting is expected to occur by the end of the third quarter of 2026.

Key Details

• Received FDA Type A meeting minutes on July 14, 2026 (meeting originally held June 10, 2026).
• Company requested clarification from the FDA on July 15, 2026.
• Plans to request and hold a Type D meeting to discuss potential NDA resubmission for reproxalap by end of Q3 2026.
• Subject of meetings: reproxalap NDA for treatment of dry eye disease.

Why It Matters

• This filing updates investors on Aldeyra’s regulatory pathway for reproxalap—receipt of FDA meeting minutes and a scheduled follow-up (Type D) meeting are procedural steps toward a potential NDA resubmission.
• The timeline (Type D expected by end of Q3 2026) gives investors a near-term regulatory milestone to watch that could affect program value and corporate outlook.
• The 8-K does not disclose FDA decisions or new data; it reports process steps and timing only.